Telomere Biology and Inflammaging | Decoding Inflammation

By Alberto Rivera, MD · 2026-06-23 · 5 min read

The Genomic Guardian: Telomeres and the Hayflick Limit

Telomeres, the repetitive TTAGGG sequences at the ends of our chromosomes, serve as protective buffers against genomic instability. During each cycle of somatic cell division, the "end-replication problem" results in the progressive loss of these sequences. Once telomeres reach a critically short length, known as the Hayflick limit, the cell undergoes a persistent DNA damage response (DDR). This is not merely a localized event but the starting point for a systemic inflammatory cascade that characterizes biological aging.

From Genomic Instability to Cellular Senescence

Critically short telomeres are recognized by the cell as double-stranded DNA breaks. This recognition activates the p53 and p21 signaling pathways, forcing the cell into a state of permanent growth arrest known as cellular senescence. While senescence initially serves as a tumor-suppressive mechanism, the accumulation of these cells becomes pathogenic. The primary driver of this pathology is the Senescence-Associated Secretory Phenotype (SASP). Senescent cells do not remain dormant; instead, they secrete a pro-inflammatory cocktail of cytokines such as IL-6 and IL-1beta, chemokines, and matrix metalloproteinases. This "inflammaging" creates a deleterious feedback loop that damages neighboring healthy tissues, degrades the extracellular matrix, and accelerates the aging process across organ systems.

The TERT Gene and the Telomerase Complex

The hTERT gene encodes the catalytic subunit of telomerase, the ribonucleoprotein enzyme responsible for maintaining telomere length by adding repetitive sequences back to chromosome ends. While telomerase is highly active during embryonic development and within adult stem cell niches, TERT expression is largely silenced in adult somatic tissues. Research into TERT reactivation or stabilization is currently at the forefront of longevity medicine. By addressing the regulation of the TERT gene, we may be able to mitigate the genomic instability that underpins the chronic inflammatory phenotype seen in geriatric populations. However, we must balance this with the risk of oncogenesis, as many cancer cells hijack TERT to achieve immortality.

Clinical Perspectives on Inflammaging

As clinicians, we must recognize that inflammaging is a fundamental driver of age-related pathologies, from atherosclerosis and type 2 diabetes to neurodegeneration. By targeting telomere biology and the subsequent SASP response, we move from treating individual symptoms to addressing the root molecular causes of biological decline. Future therapeutic interventions focusing on senolytics—agents that selectively eliminate senescent cells—and telomerase modulators hold significant promise for extending the human healthspan and reducing the burden of chronic inflammation.